These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 30557164)
1. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia. Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164 [TBL] [Abstract][Full Text] [Related]
2. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful? Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents. Ahn S; Rice TW; Yeung SJ; Cooksley T Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032 [TBL] [Abstract][Full Text] [Related]
4. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center. Nguyen M; Jacobson T; Torres J; Wann A Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593 [TBL] [Abstract][Full Text] [Related]
5. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review. Pherwani N; Ghayad JM; Holle LM; Karpiuk EL Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185 [TBL] [Abstract][Full Text] [Related]
6. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice. Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174 [TBL] [Abstract][Full Text] [Related]
7. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs]. Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients. Monuszko KA; Albright B; Katherine Montes De Oca M; Thao Thi Nguyen N; Havrilesky LJ; Davidson BA Gynecol Oncol Rep; 2021 Aug; 37():100853. PubMed ID: 34504931 [TBL] [Abstract][Full Text] [Related]
9. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Ahn S; Lee YS; Lim KS; Lee JL Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568 [TBL] [Abstract][Full Text] [Related]
10. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215 [TBL] [Abstract][Full Text] [Related]
11. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department. Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827 [TBL] [Abstract][Full Text] [Related]
12. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia? Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990 [TBL] [Abstract][Full Text] [Related]
13. Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department? Chen AY; Gottlieb M; Vilke GM; Coyne C J Emerg Med; 2023 Jan; 64(1):111-118. PubMed ID: 36641256 [TBL] [Abstract][Full Text] [Related]
14. Predictive performance of the quick Sequential Organ Failure Assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia. Kim M; Ahn S; Kim WY; Sohn CH; Seo DW; Lee YS; Lim KS Support Care Cancer; 2017 May; 25(5):1557-1562. PubMed ID: 28062972 [TBL] [Abstract][Full Text] [Related]
15. Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study. Bhardwaj PV; Emmich M; Knee A; Ali F; Walia R; Roychowdhury P; Clark J; Sridhar A; Lagu T; Loh KP Support Care Cancer; 2021 Oct; 29(10):5905-5914. PubMed ID: 33761002 [TBL] [Abstract][Full Text] [Related]
16. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors. Bitar RA Perm J; 2015; 19(3):37-47. PubMed ID: 26176568 [TBL] [Abstract][Full Text] [Related]
17. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Uys A; Rapoport BL; Anderson R Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637 [TBL] [Abstract][Full Text] [Related]